Tractive Acquires Whistle from Mars Petcare to Accelerate Leadership in Global Pet Tech Market
28.7.2025 14:00:00 EEST | Business Wire | Press release
Tractive, the global leader in GPS tracking and pet health insights, today announced it has acquired Whistle, the connected pet wearable brand owned by Mars Petcare. This strategic acquisition adds Whistle’s customer base and technology assets to Tractive, reinforcing its leadership in the fast-growing pet tech market. Founded in Austria in 2012, Tractive has established itself as the world's leading provider of smart GPS and health trackers for pets, serving over 1.4 million active users worldwide with millions of devices sold globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250728342394/en/
Whistle is now part of Tractive
Whistle customers will have the option to transition to Tractive’s highly rated platform, named #1 by Consumer Reports and recognized as the top pet tracker on Amazon and top pick by The New York Times Wirecutter. The move gives Whistle users access to Tractive’s latest innovations, including resting heart rate and respiratory rate monitoring, a first in the pet GPS and health tracking category.
"This acquisition is a defining moment for Tractive," said Michael Hurnaus, CEO and co-founder of Tractive. "It strengthens our U.S. footprint, scales our customer base, and allows us to bring cutting-edge wellness technology to even more pet parents around the world. In the United States, Whistle is recognized as the original pioneer in pet tracking and activity monitoring. Since 2013, Tractive and Whistle have been innovating in parallel, Tractive in Europe and Whistle in the U.S., shaping the future of pet tracking and wellness. Now, by joining forces, we're combining the strengths of two market leaders to reinforce Tractive's global leadership and accelerate our mission to improve pet safety and health worldwide."
Tractive's smart trackers enable pet owners to locate their animals in real time and monitor comprehensive health metrics including activity, sleep, barking behavior, resting heart rate, and respiratory rate, with millions of health data points analyzed daily to generate valuable insights that ensure safety, well-being, and peace of mind for pet owners across North America and Europe.
With the pet industry, and especially connected pet care, growing much faster than overall consumer spending, Tractive is uniquely positioned to lead the future of pet wellness and tracking globally. Its devices offer long battery life, live GPS, health alerts, and now vital sign monitoring—delivered through a seamless subscription model across more than 175 countries.
About Tractive
Tractive is the global leader in health monitoring and GPS tracking for dogs and cats, on a mission to help pet parents keep their pets safe, healthy, and happy. Trusted by 1.4 million active users worldwide, Tractive is transforming pet care through data-driven health insights and innovative technology. Headquartered in Austria with offices in the U.S. and Germany, Tractive works with all major cellular providers across North America and Europe to ensure best-in-class coverage wherever pets roam.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250728342394/en/
Contacts
Media Contacts:
Andrew Bleiman, EVP Tractive North America
andrew.bleiman@tractive.com
Sarah Doyle, VP Global Corporate Communications
sarah.doyle@antechdx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom